Published in Hepatitis Weekly, December 6th, 2004
In a presentation entitled "phase I/II Double-Blind, Randomized, Placebo-Controlled Study of the Novel Anti-HBV Agent LB80380/ANA380 in Patients with Chronic HBV Infection," Man-Fung Yuen of the University of Hong Kong reported that ANA380 reduced viral load by an average of 3.4 log10 units, or more than 99.9%, in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly